Monday, September 25, 2017
Educational Session - Biology, diagnosis and management of APL
Chairmen: M. Alcalay, M.A. Sanz
L. Cicconi
Pathogenesis, diagnosis and monitoring of Acute Promyelocytic Leukemia
P. Montesinos
Front-line Therapy in Acute Promyelocytic Leukemia
L. Ades
Acute Promyelocytic Leukemia Therapy of relapse
Session V - Molecular bases of targeted therapy and resistance
Chairmen: F. Grignani, W.H. Miller
P. G. Pelicci
Regulation of self renewal in cancer stem cells
M. Giannì
The S100 calcium binding protein A3 binds directly and specifically to RARα and PML-RAR and modulates the activity of APL cells
Session VI - Genome and epigenome of APL
Chairmen: L. Degos, P.G. Pelicci
W. H. Miller
Mechanisms of response and resistance to epigenetic therapies
Oral Session I - APL biology I
Chairmen: S. Minucci, C. Nervi
C. Bally
Whole exome analysis of relapsing patients with Acute Promyelocytic Leukemia
L. Iaccarino
PML and RARA mutations in relapsed Acute Promyelocytic Leukemia
O. H. Krämer
Molecular analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in Acute Promyelocytic Leukemia cells
M. S. Tallman
Mutations in Acute Promyelocytic Leukemia are Similar at Diagnosis and Relapse and ETV6 may be a Molecular Biomarker of Decreased Disease-Free Survival and High-Risk Disease Independent of White Blood Cell Count
R. Kolhe
Acute Promyelocytic Leukemia: molecular characterization by cancer immune profiling may identify patients at risk of early death
Session VII - Early death and population-based studies
Chairmen: B. Löwenberg, E. Rego
M. Seftel
Observational studies in APL: what have we learned and what can we still learn?
S. Lehmann
Early deaths as the most significant threat to APL patients in real life
H. H. Zhu
Early Death and Outcomes of Patients with APL using arsenic and ATRA as First-Line treatment: a real world study
F. Ravandi
Long-term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
Session VIII - Management of APL in developing countries I
Chairmen: N. Berliner, L. Adès
E. Rego
Long term follow up of the International Consortium on Acute Promyelocytic Leukemia: achievements and limitations
M. Chandy
Progress and Constraints in treating APL in India
M. Saidi
Epidemiology, diagnosis, clinical features and outcome of APL patients treated in Batna Against Cancer Center (Algeria)
D. Freigeiro
Pediatric acute promyelocytic leukemia (apl) in latin american children. is it possible to work together? The Clehop initiative
Teva sponsored symposium Next-generation APL leaders: Teva's award for young hematologists
Chairman: B. Löwenberg
H. De Thé
Arsenic, a targeted curative therapy of APL
Tuesday, September 26, 2017
Oral Session II - APL biology II
Chairmen: S.K. Hasan, C. Thiede
S. Masciarelli
Retinoic Acid and Arsenic Trioxide sensitize Acute Myeloid Leukemia cells to ER stress
N. I. Noguera
PML-RARa interferes with Nrf2 function in Acute Promyelocytic Leukemia Cells
M. Llop
Molecular analysis of acute promyelocytic leukemia by next generation sequencing
N. Balasundaram
Metabolic catastrophe of arsenic trioxide resistant cells in Acute Promyelocytic Leukemia
J. Labrador
Clinical significance of complex karyotype at diagnosis in Patients with Acute Promyelocytic Leukemia Treated with ATRA and chemotherapy based PETHEMA trials
Session IX - Update in frontline trials I
Chairmen: M. Seftel, M.S. Tallman
G. Avvisati
Update of the Italian-German study APL 0406
J. Li
Retinoic Acid and Arsenic Trioxide with or without Chemotherapy for Acute Promyelocytic Leukemia with Different Risk Stratifications: An Interim Analysis of China APL 2012 Study
A. Takeshita
Recent results from the prospective studies on APL in the Japan Adult Leukemia Study Group (JALSG)
L. Adès
Update of APL 2006 trial results
M. A. Sanz
Update on PETHEMA trials
Session X - Update in frontline trials II
Chairmen: M. Seftel, M. Tallman
H. Iland
The ALLG approach to incorporating arsenic trioxide: APML4 (final analysis) and APML5 (encapsulating therapy)
V. Mathews
Potential for non-conventional agents in upfront and relapsed APL
N. Russell
Long term follow up of the NCRI AML17 trial of attenuated arsenic trioxide and ATRA therapy for newly diagnosed and relapsed Acute Promyelocytic Leukaemia
E. Estey
Implications for AML Raised by “Chemofree” ATO+ATRA in APL
Session XI - The APL coagulopathy
Chairmen: G. Avvisati, M. Chandy
A. Falanga
APL fatal bleeding and thrombosis in the ATRA era
P. Montesinos
Thrombohemorrhagic disorders in APL: the unsolved issue
M. Frech
Differential expression of tissue factor F3 and nuclear receptors 4A in early death acute promyelocytic leukemia patients
H. H. Zhu
The impact of oral arsenic and ATRA on conagulopathy in APL
Session XII - APL in children and the elderly
Chairmen: R.A. Larson, F. Locatelli
O. Abla
Obesity and Initial High White Blood Cell Count Are Predictors of Thrombo-hemorrhagic Early Death in Children and adolescents with t(15;17) positive Acute Promyelocytic Leukemia
A. Testi
Risk-adapted ATRA and chemotherapy in children with newly diagnosed acute promyelocytic leukemia: a 15-year multicentric experience
D. Martínez Cuadrón
Characteristics and outcome of elderly APL patients treated with PETHEMA protocols
M. Kutny
Toxicity in Pediatric Patients Treated with ATRA and Arsenic Trioxide Induction: A Report from the Children's Oncology Group Study AAML1331
Oral Session III - APL in children and elderly
Chairmen: H. Iland, N. Russell
S. Al-Hadad
Outcome of acute promyelocytic leukemia patients Experience of Children Welfare Teaching Hospital (2010-2015) Baghdad, Iraq
H. H. Zhu
Oral arsenic and retinoic acid for children with non-high-risk APL
M. A. Kutny
Arsenic Trioxide Consolidation Results in Excellent Survival in Young Children as well as Older Children and Adolescents with Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631
L. Adès
Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial)
L. B. Huang
Comparing Arsenic Trioxide with Realgar-Indigo naturalis formula in children with Acute Promyelocytic Leukemia: An Interim Report of Multicenter and Randomized clinical Trial
Oral Session IV - Clinical studies and prognostic factors
Chairmen: L. Degos, S. Lehmann
E. Lengfelder
Frontline therapy of acute promyelocytic leukemia: randomized comparison of ATRA and intensified chemotherapy including high dose cytosine-arabinoside versus ATRA and anthracyclines -
A prospective multicenter randomized clinical trial of the German Acute Myeloid Leukemia Cooperative Group (AMLCG).
H. H. Zhu
Oral arsenic and retinoic acid for high-risk Acute Promyelocytic Leukemia
B. Boluda
Clinical significance of CD56 expression in patients with de novo acute promyelocytic leukemia treated with the PETHEMA LPA96, LPA99 and LPA2005 protocols: an updated analysis
R. Rodriguez-Veiga
Characteristics and clinical outcome of patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols
T. Maia
Retrospective analysis of early mortality in a cohort of patients with Acute Promyelocytic Leukemia
